News >

Safety Analysis Supports Adjuvant T-DM1 Use in Early HER2+ Breast Cancer

Caroline Seymour
Published: Monday, Oct 14, 2019

Michael Untch, MD, PhD

Michael Untch, MD, PhD

Findings from a secondary analysis of the phase III KATHERINE trial showed that adjuvant ado-trastuzumab emtansine (T-DM1; Kadcyla) has a comparable safety profile with adjuvant trastuzumab (Herceptin) regarding the rate of peripheral neuropathy, thrombocytopenia, and CNS recurrence in patients with HER2-positive early breast cancer.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication